Risk / RewardSo in about 5 weeks from now we will see that PMN310 has no Aria-E and can dose up to 40mg, with significant blood barrier payloads. Now the end of the road for us will be in 6 months of phase 1B where we will show selectivity to oligomers and the percentage of efficacy in stopping the propagation of toxicity. This will lead to big pharma arriving in drives with their check books and ultimate offers on the table. The risk of course is that this has no cognitive effect and the years of science is wrong, but don't forget the primates that proved otherwise.